Tumor-specific hyperthermia with aptamer-tagged superparamagnetic nanoparticles.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Targeted therapy minimizes side effects in cancer treatment.
• Magnetic hyperthermia, using nanoparticles (NPs), can enhance chemo- or radiotherapy.
• Developing targeted NPs is crucial for effective and safe cancer therapies.

Purpose of the Study:

• To construct and evaluate dextran-coated ferric oxide NPs conjugated with anti-HER2 aptamers for targeted magnetic hyperthermia.
• To assess the specificity of aptamer-tagged NPs towards HER2-expressing cancer cells.
• To compare the efficacy and required dosage of targeted vs. non-targeted NPs in inducing hyperthermia.

Main Methods:

• Ferric oxide NPs were coated with dextran and conjugated with anti-HER2 aptamers.
• Specificity was tested on HER2-overexpressing (SK-BR3) and non-expressing (U-87 MG) cell lines.
• Cellular uptake was confirmed using fluorescence microscopy and fluorescence-activated cell sorting.

Main Results:

• Aptamer-tagged NPs demonstrated high specificity for HER2-expressing SK-BR3 cells.
• A ninetyfold lower dose of tagged NPs achieved ~50% cell killing in SK-BR3 cells compared to non-tagged NPs.
• U-87 MG cells showed near 100% viability, indicating minimal effect from tagged NPs.

Conclusions:

• Aptamer-tagged NPs are highly specific and effective for targeted magnetic hyperthermia.
• Targeted NPs enable significantly lower therapeutic doses, reducing potential side effects.
• This approach holds promise for improving the safety and efficacy of cancer treatment.